Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-014 adjuvant intismeran with or without MK-3475A versus placebo in resected high-risk stage I NSCLC
jRCT2021260028Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of intismeran autogene and berahyaluronidase alfa + pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Disease-free survival. Started Sep 2026; status: recruiting.
02
Drugs
intismeran autogeneberahyaluronidase alfa + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021260028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260028.